Pharma BD Deal Intelligence

Eli Lilly and Company / Juvena Therapeutics, Inc.

2025 · Licensing/Option · $650M · Complete

Juvena Therapeutics and Eli Lilly entered a global licensing and multi-target research collaboration to discover, develop and commercialize drug candidates that improve muscle health and body composition, using Juvena's JuvNET machine-learning platform for mining the stem-cell secretome. Juvena receives an undisclosed upfront payment and equity investment plus more than $650 million in potential development and commercialization milestones.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Eli Lilly and Company deals